Huateng Pharma Highlights Key Intermediate for Aficamten
Changsha, China – September 22, 2025 – Hunan Huateng Pharmaceutical Co., Ltd. (“Huateng Pharma”), a global supplier of high-quality pharmaceutical intermediates and PEG derivatives, today announced the availability of 1-Methyl-1H-Pyrazole-4-Carboxylic Acid (CAS No. 5952-92-1), a critical intermediate in the synthesis of Aficamten (CK-274), an investigational cardiac myosin inhibitor currently in Phase 3 clinical trials for the treatment of hypertrophic cardiomyopathy (HCM).
Aficamten is designed to reduce excessive cardiac contractility by selectively modulating cardiac myosin, offering a promising treatment option for patients with HCM, a disease that can lead to heart failure and serious arrhythmias. With Phase 3 trials underway, aficamten represents a significant advancement in cardiovascular drug development.
1-Methyl-1H-Pyrazole-4-Carboxylic Acid plays a vital role as a building block in the synthesis of aficamten. By providing this intermediate at high purity and consistent quality, Huateng Pharma supports drug developers in both research and scale-up production.
“As aficamten advances through late-stage clinical development, we are fully prepared to support global partners with reliable supply of 1-Methyl-1H-Pyrazole-4-Carboxylic Acid,” said Brenda Xie, Sales Manager at Huateng Pharma. “We can provide this intermediate from gram to commercial scale, ensuring seamless transition once the drug reaches the market.”
Huateng Pharma remains committed to advancing pharmaceutical innovation by delivering high-quality intermediates, PEG derivatives, and CDMO services from R&D through to commercial production.
For more information, visit https://us.huatengsci.com
About Huateng Pharma
Hunan Huateng Pharmaceutical Co., Ltd. is a world-leading supplier of PEG derivatives and pharmaceutical intermediates, offering comprehensive support to the biopharmaceutical industry. From laboratory-scale R&D to commercial-scale production, Huateng Pharma provides innovative solutions to accelerate drug development worldwide.